Gastrointestinal complications in renal transplant recipients

Transplant International

Volumn 18, Issue 6, 2005, Pages 643-650

  Ponticelli, Claudio ^a,c   Passerini, Patrizia ^b  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c NONE   (Italy)

Author keywords

Gastrointestinal complications; Immunosuppressive therapy; Renal transplantation; Renal transplantation complications

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; AMPICILLIN; AZATHIOPRINE; COLCHICINE; COLESTYRAMINE; METRONIDAZOLE; MISOPROSTOL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAPAMYCIN; VANCOMYCIN;

COLON CANCER; COLON DISEASE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; ENTERITIS; ESOPHAGITIS; GASTROINTESTINAL DISEASE; HUMAN; KIDNEY TRANSPLANTATION; LEUKOPLAKIA; MOUTH LESION; NAUSEA; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STOMACH DISEASE; VIRUS INFECTION; VOMITING; DUODENUM DISEASE; ESOPHAGUS DISEASE; GASTROINTESTINAL TUMOR; POSTOPERATIVE COMPLICATION;

COLONIC DISEASES; DIARRHEA; DUODENAL DISEASES; ESOPHAGEAL DISEASES; GASTROINTESTINAL DISEASES; GASTROINTESTINAL NEOPLASMS; HUMANS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; STOMACH DISEASES;

EID: 23244451207     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2005.00134.x     Document Type: Review

References (68)

1. Hardinger K, Brennan DC, Lowell J, Schnitzler MA. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 2004; 17: 609.
2. Sarkio S, Halme L, Kyllonen L, Salmela K. Severe gastrointestinal complications after 1515 adult kidney transplantations. Transpl Int 2004; 17: 505.
3. Thomason JM, Seymour RA, Ellis J. The periodontal problems and management in renal transplant patient. Ren Fail 1994; 16: 731.
4. Spoildorio LC, Spoildorio DM, Neves KA, Gonzaga HF, Almeida OP. Morphological evaluation of combined effects of cyclosporine and nifedipine on gingival overgrowth in rats. J Periodontal Res 2002; 37: 192.
5. Nash MM, Zaltzman. Efficacy of azithromicin in the treatment of cyclosporine-induced gingival hyperplasia in renal transplant recipients. Transplantation 1998; 65: 1611.
6. Matsumoto CS, Fishbein TM, Kaufman SS. Gastrointestinal infections in solid organ transplant recipients. Curr Opin Organ Transplant 2004; 13: 406.
7. Van Gelder T, ter Meulen CG, Hené R, Weimar W, Hoistma A. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003; 75: 788.
8. Hernandez G, Hernandez G, Arriba L, et al. Rapid progression from oral leukoplakia to carcinoma in an immunosuppressed liver transplant recipient. Oral Oncol 2003; 39: 87.
9. Frick T, Fryd DS, Goodale RL, Simmons RL, Sutherland DE, Najarian JS. Incidence and treatment of candida esophagitis in patients undergoing renal transplantation. Data from the Minnesota prospective randomized trial of cyclosporine versus antilymphocyte globulin-azathioprine. Am J Surg 1988; 155: 311.
10. Helderman JH, Goral S. Gastrointestinal complications of transplant immunosuppression. J Am Soc Nephrol 2002; 13: 277.
11. Berhend M. Mycophenolate mofetil: suggested guidelines for use in kidney transplantation. BioDrugs 2001; 15: 37.
12. Knoll GA, MacDonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14: 2381.
13. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17: 200.
14. Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004; 4: 231.
15. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004; 4: 237.
16. Kestens PJ, Alexandre GPJ. Gastroduodenal complications after transplantation. Clin Transplant 1988; 2: 221.
17. Benoit G, Moukarzel M, Verdelli G, et al. Gastrointestinal complications in renal transplantation. Transpl Int 1993; 6: 45.
18. Chen KJ, Chen CH, Cheng CH, Wu MJ, Shu KH. Risk factors for peptic ulcer disease in renal transplant recipients - 11 years of experience from a single center. Clin Nephrol 2004; 62: 14.
19. Kang JY. The gastrointestinal tract in uremia. Dig Dis Sci 1993; 38: 257.
20. Sarkio S, Rautelin H, Kyllonen L, Honkanen E, Salmela K, Halme L. Should Helicobacter pylori infection be treated before kidney transplantation? Nephrol Dial Transplant 2001; 16: 2053.
21. Bjarnason I. Entering coating of mycophenolate sodium: a rational approach to limit topic gastrointestinal lesions and extend the therapeutic index of mycophenolate. Transplant Proc 2001; 33: 3238.
22. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994; 236: 619.
23. Battistel M, Plebani M, Di Mario F, Jocic M, Lippe IT, Holzer P. Chronic nicotine intake causes vascular dysregulation in the rat gastric mucosa. Gut 1993; 34: 1688.
24. Guslandi M, Sorghi M, Pontikaki I, Tittobello A. Gastric microcirculation and bicarbonate production in heavy smokers. Eur J Gastroenterol Hepatol 1995; 10: 985.
25. Logan AJ, Morris-Stiff GJ, Bowrey DJ, Jurewicz WA. Upper gastrointestinal complications after renal transplantation: a 3-year sequential study. Clin Transplant 2002; 16: 163.
26. Calzone A, Naso P, Puliatti C. Massive gastrointestinal hemorrhage in a renal transplant recipient due to visceral Kaposi's sarcoma. Endoscopy 2002; 34: 179.
27. Aull MJ, Buell JF, Peddi VR, et al. Israel Penn International Transplant Tumor Registry: MALToma: a Helicobacter pylori-associated malignancy in transplant patients: a report from the Israel Penn International Transplant Tumor Registry with a review of published literature. Transplantation 2003; 75: 225.
28. Amaro R, Neff GW, Karnam US, Tzakis AG, Raskin JB. Acquired hyperplastic gastric polyps in solid organ transplant patients. Am J Gastroenterol 2002; 97: 2220.
29. Nash CL, Price LM, Stewart DA, Sepandj F, Yilmaz S, Barama A. Early gastric post-transplantation lymphoproliferative disorder and H. pylori after kidney transplantation: a case report and review of the literature. Can J Gastroenterol 2000; 14: 721.
30. Hsi ED, Singleton TP, Swinnen L, Dunphy CH, Alkan S. Mucosa-associated lymphoid tissue-type lymphomas occurring in post-transplantation patients. Am J Surg Pathol 2000; 24: 100.
31. Halme L, Hockerstedt K, Lautenschlager I. Cytomegalovirus infection and development of biliary complications after liver transplantation. Transplantation 2003; 75: 1853.
32. Peter A, Telkes G, Varga M, Sarvary E, Kovalszky I. Endoscopic diagnosis of cytomegalovirus infection of upper gastrointestinal tract in solid organ transplant recipients: Hungarian single experience. Clin Transplant 2004; 18: 580.
33. Andreoni KA, Pelletier RP, Elkhammas EA, et al. Increased incidence of gastrointestinal surgical complications in renal transplant recipients with polycystic disease. Transplantation 1999; 67: 262.
34. Bobak DA. Gastrointestinal infections caused by cytomegalovirus. Curr Infect Dis Rep 2003; 5: 101.
35. Chang HR, Lian JD, Chan CH, Wong LC. Cytomegalovirus ischemic colitis of a diabetic renal transplant recipient. Clin Transplant 2004; 18: 100.
36. Sellin JH. The pathophysiology of diarrhea. Clin Transplant 2001; 15(Suppl. 4): 2.
37. Keven K, Keven K, Basu A, et al. Clostridium difficile colitis in patients after kidney and pancreas-kidney transplantation. Transpl Infect Dis 2004; 6: 10.
38. Pescovitz MD, Navarro MT. Immunosuppressive therapy and post-transplantation diarrhea. Clin Transplant 2001; 15(Suppl. 4): 23.
39. Wang K, Zhang H, Li Y, et al. Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review. Transplant Proc 2004; 36: 2068.
40. Neerman MF, Boothe DM. A possible mechanism of gastrointestinal toxicity posed by mycophenolic acid. Pharmacol Res 2003; 47: 523.
41. Maes BD, Lemahieu W, Kuypers D, et al. Differential effect of diarrhea on FK 506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. Am J Transplant 2002; 2: 989.
42. Schaier M, Wendt C, Zeier M, Ritz E. Clostridium difficile diarrhoea in the immunosuppressed patient-update on prevention and management. Nephrol Dial Transplant 2004; 19: 2432.
43. Dominguez Fernandez E, Albrecht KH, Heemann U, et al. Prevalence of diverticulosis and incidence of bowel perforation after kidney transplantation in patients with polycystic kidney disease. Transpl Int 1998; 11: 28.
44. Korkmaz M, Gur G, Yilmaz U, Karakayali H, Boyacioglu S, Haberal M. Colonoscopy is a useful diagnostic tool for transplant recipients with lower abdominal symptoms. Transplant Proc 2004; 36: 190.
45. Dee SL, Butt K, Ramaswami G. Intestinal ischemia. Arch Pathol Lab Med 2002; 126: 1201.
46. Lederman ED, Conti DJ, Lempert N, Singh TP, Lee EC. Complicated diverticulitis following renal transplantation. Dis Colon Rectum 1998; 41: 613.
47. Maurer JR. The spectrum of colonic complications in a lung transplant population. Ann Transplant 2000; 5: 54.
48. Bobak DA. Gastrointestinal complications caused by cytomegalovirus. Curr Infect Dis Rep 2003; 5: 101.
49. Lee CJ, Lian JD, Chang SW, et al. Lethal cytomegalovirus ischemic colitis presenting with fever of unknown origin. Transpl Infect Dis 2004; 6: 124.
50. Remzi FH. Colonic complications of organ transplantation. Transplant Proc 2002; 34: 2119.
51. Riley TR, Schoen RE, Lee RG, Rakela J. A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease. Am J Gastroenterol 1997; 92: 279.
52. Stewart T, Henderson R, Grayson H, Opelz G. Reduced incidence of rectal cancer, compared to gastric and colonic cancer, in a population of 73,076 men and women chronically immunosuppressed. Clin Cancer Res 1997; 3: 51.
53. Penn I. De novo cancers in organ allograft recipients. Curr Opin Organ Transplant 1998; 3: 188.
54. Shehab TM, Hsi ED, Poterucha JJ, Gunaratnam NT, Fontana RJ. Helicobacter pylori-associated gastric MALT lymphoma in liver transplant recipients. Transplantation 2001; 71: 1172.
55. Lee SK, Lee YC, Chung JB, et al. Low grade gastric mucosa associated lymphoid tissue lymphoma. Treatment strategies based on 10 year follow-up. World J Gastroenterol 2004; 10: 223.
56. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222.
57. Cohen JI. Epstein-Barr virus and the immune system. Hide and seek. JAMA 1997; 278: 510.
58. Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res 2004; 10: 803.
59. Pagano JS, Blaser M, Buendia MA, Damania B, et al. Infectious agents and cancer: criteria for a causal relation. Semin Cancer Biol 2004; 14: 453.
60. Holmes DR, Orban-Eller K, Karrer FR, et al. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56 months follow-up and outcome. Transplantation 2002; 74: 367.
61. Comoli P, Labirio M, Basso S, et al. Infusion of autologous Epstein-Barr virus (EBV) - specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002; 99: 2592.
62. Nepomuceno RR, Balatoni CE, Natkuman Y, Snow AL, Krams SM, Martinez OM. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein-Barr virus B cell lymphomas. Cancer Res 2003; 63: 4472.
63. Majiewski M, Korecka M, Joergensen J, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003; 63: 4472.
64. Tsai DE, Hardy CL, Tomaszwesky JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder in adult solid organ transplant patients. Am J Transplant 2001; 71: 1076.
65. Milfield N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in posttransplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000; 11(Suppl. 1): 113.
66. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359.
67. Gulley ML, Swinnen LH, Plaisance KT, et al. Tumor origin and CD20 expression in posttransplant lymphoproliferative occurring in solid organ transplant recipients: implication for immune based therapy. Transplantation 2003; 79: 959.
68. Gottschalk S, Heslop H, Rooney C. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma 2005; 46: 1.